Skip to search formSkip to main contentSkip to account menu

E 643

Known as: E-643, E643 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryTo determine whether E-643, a new α-blocking agent, would reduce the blood pressure, regardless of the posture, a 1 mg… 
1986
1986
The acute hemodynamic effect of the selective alpha1-antagonist, 2-[4-(n-butyryl)-homopiperazine-1-y1]-4-amino-6,7-dimethoxy… 
1982
1982
Radiolabeled E-643, a newly developed antihypertensive compound, bound specifically to a preparation obtained from rat brain with… 
Highly Cited
1981
Highly Cited
1981
Effectiveness of E-643, a newly developed alpha-blocker, and four alpha-antagonists in blocking pre- and postsynaptic alpha… 
1981
1981
Using the isolated and blood-perfused dog atrial preparation, chronotropic and inotropic responses to 3 kinds of alpha-adrenergic… 
1980
1980
Postsynaptic alpha-receptor blocking properties of E-643 were studied in vivo and in vitro and compared with these same… 
1980
1980
To further clarify the hypotensive mechanism of adrenergic alpha blockers, effects of several alpha blockers on systemic blood… 
1980
1980
The effect of 2-[N-(n-butyloyl)homopiperazin-N'-yl]-4-amino-6,7-dimethoxy quinazoline hydrochloride (E-643), a new alpha… 
1977
1977
Using a continuous systolic monitor, effects of oral administration of three alpha-adrenergic blockers, i.e. phenoxybenzamine…